H-1 PV is able to slow down and stabilize the growth of nasopharyngeal carcinoma in humanized SCID mice.

<p>Immunodeficient SCID mice (Severe combined Immunodeficiency) were subcutaneously xenotransplanted with tumors of nasopharyngeal carcinoma (NPC) induced by C15 cells (human primary tumor cells of NPC). <b>A</b>. Timeline which summarizes the experimental protocol followed. After development of visible tumors, SCID mice were splenectomized and reconstituted (i.p) or not with 50.10⁶ human PBMC. At the same moment they also received or not H-1PV directly injected within the tumor. SCID mice received only one injection of H-1 PV throughout the protocol. <b>B</b>. Results are presented in Tumor Volume Index versus days post-treatment. There is a progressive increase in tumor size for the four groups of mice. Only the groups, which did not receive H-1 PV, saw their tumors grow to 6–7 times the original size. <b><i>H-1 PV stabilize the growth of nasopharyngeal carcinoma in humanized SCID mice</i></b>. In two groups of mice that received H-1 PV, the growth of the tumor does not exceed a maximum of three times the size of the primary tumor. The size of these tumors stabilized to stay below the maximum threshold of 3. <i>Representative data from 2 independent experiments</i>.